https://scholar.dgist.ac.kr/handle/20.500.11750/10165 2026-04-04T10:04:53Z 2026-04-04T10:04:53Z Lim, S- M. Kim, Beom Soo Yu, Wookyung Choi, Seong-Kyoon Jo, A. Seah, E. Kim, C. Han, S. Cho, B. C. Kim, Hee-Yeon https://scholar.dgist.ac.kr/handle/20.500.11750/60085 2026-02-11T12:40:12Z 2025-09-07T15:00:00Z

Title: Effect of JIN-A02, a Novel 4Th-Generation EGFR-TKI, on Multiple EGFR Mutations in Comparison With 3Rd-Generation EGFR-TKIs Author(s): Lim, S- M.; Kim, Beom Soo; Yu, Wookyung; Choi, Seong-Kyoon; Jo, A.; Seah, E.; Kim, C.; Han, S.; Cho, B. C.; Kim, Hee-Yeon Abstract: JIN-A02, a novel fourth-generation tyrosine kinase inhibitor (TKI) targeting the epidermal growth factor receptor (EGFR) C797S mutation, is currently undergoing phase 1/2 clinical trials in patients with EGFR-mutated non-small cell lung cancer (NSCLC) in Korea, the USA, and Thailand (NCT05394831). NSCLC patients harboring acquired EGFR C797S mutations often exhibit co-occurring mutations, such as exon 19 deletions or T790M, as a result of targeted therapies, leading to tumor tissue heterogeneity. This heterogeneity significantly limits therapeutic options for these patients. To address this challenge, there is an unmet need for the development of fourth-generation EGFR-TKIs capable of targeting multiple EGFR mutations and effectively suppressing heterogeneous tumor tissues. With a view to evaluating the activity of JIN-A02 against common EGFR mutations (including T790M), we conducted an in silico study to estimate its binding affinity compared with third-generation EGFR-TKIs along with an in vitro study to calculate its inhibitory concentration (IC90) in EGFR-mutated cell lines.

2025-09-07T15:00:00Z Jeon, Won Bae Park, Hyun Soo Kim, Jiyoon Lee, Yejin Choi, Yoori Cheon, Gi Jeong https://scholar.dgist.ac.kr/handle/20.500.11750/59288 2025-12-29T05:10:11Z 2025-11-18T15:00:00Z

Title: Pharmacokinetics, biodistribution, and neurohistopathological toxicity of self-assembling polypeptide-drug conjugates following intrapontine convection-enhanced delivery Author(s): Jeon, Won Bae; Park, Hyun Soo; Kim, Jiyoon; Lee, Yejin; Choi, Yoori; Cheon, Gi Jeong Abstract: Pediatric diffuse midline glioma (DMG) is a uniformly lethal tumor, and patients diagnosed with DMG are in urgent need of novel therapeutics, as no effective treatment options currently exist for this fatal disease. Excellamol has developed self-assembling polypeptide-drug conjugates for oncology (OncoPDCs), which consist of IL13Ra2-binding ligands, intrinsically disordered domains, and the cytotoxic agent Exatecan. Upon CED into the brain, OncoPDCs undergo phase transition to form self-assembled coacervates, which are expected to exhibit prolonged retention within the brain. Preclinical efficacy studies have previously demonstrated the feasibility and therapeutic potential of OncoPDCs in high-grade gliomas. In this study, we evaluated the retention properties of OncoPDCs by comparing the pharmacokinetics of a free fluorescent dye (AZDye647), a dye-labeled polypeptide (XM182-AZDye647), and an OncoPDC (XM182-Exatecan) following convection-enhanced delivery into the pons of naive Balb/c-nu mice and Sprague Dawley rats. Free AZDye647 was rapidly cleared from the brain, with a clearance half-life of 0.38 days. In contrast, XM182-AZDye647 demonstrated prolonged retention in the pons, with a half-life of 16.5 days. To further assess drug kinetics and biodistribution, XM184-Exatecan, a surrogate of XM182-Exatecan, was labeled with iodine-125 (125I), and the resulting 125I-XM184-Exatecan was infused via CED into the rat pons. 125I-XM184-Exatecan exhibited biphasic clearance kinetics: an initial rapid elimination phase (half-life = 2.7 days) followed by a slower clearance phase (half-life = 14.9 days). 125I radioactivity was detected only in the urinary bladder, stomach, and thyroid, with the combined radioactivity accounting for less than 5% of the infused dose. Importantly, no histopathological toxicity was observed in the pons of rats treated with XM182-Exatecan, supporting the safety of this modality. In conclusion, the integration of self-assembling OncoPDC XM182-Exatecan with CED offers a promising therapeutic strategy for the treatment of DMG by significantly enhancing intrapontine drug residence time.

2025-11-18T15:00:00Z Manattayil, Jyothsna Lal Krishna, A.S. Prosad, Asish Sarkar, Purba Kim, Hyunmin Bhat, Ramray Raghunathan, Varun https://scholar.dgist.ac.kr/handle/20.500.11750/58939 2025-08-22T09:40:09Z 2022-10-17T15:00:00Z

Title: Sub-diffraction Second Harmonic Generation Microscopy using Particle Swarm Optimized Phase Mask Author(s): Manattayil, Jyothsna; Lal Krishna, A.S.; Prosad, Asish; Sarkar, Purba; Kim, Hyunmin; Bhat, Ramray; Raghunathan, Varun Abstract: Super-resolution in second harmonic generation microscopy is demonstrated using fabricated multi-step phase masks designed using particle-swarm optimization. Experimentally obtained maximum improvement in resolution of 39% is used for quartz test feature and collagen imaging. © 2022 The Author(s)

2022-10-17T15:00:00Z Jin, Chaewon Choi, Hongsoo Kim, Jin-Young https://scholar.dgist.ac.kr/handle/20.500.11750/58670 2025-07-25T03:22:17Z 2021-10-10T15:00:00Z

Title: 96-WELL FORMAT-BASED MICROFLUIDIC PLATFORM FOR HIGH-THROUGHPUT DRUG SCREENING Author(s): Jin, Chaewon; Choi, Hongsoo; Kim, Jin-Young Abstract: In this study, a simple and robust microfluidic platform is presented, which can interconnect and culture multiple microtissues (MTs) as 96-well format-based platform. Human colon cancer (HCT116) MTs were cultured over 4 days and exposed to various concentrations of endoxifen. Drug resistance was observed when HCT116 MTs were cultured under perfusion conditions. It addresses the feasibility of our microfluidic platform for more complex and comprehensive pharmacokinetic study in an in vivo-like in vitro physiological environment. © 2021 MicroTAS 2021 - 25th International Conference on Miniaturized Systems for Chemistry and Life Sciences. All rights reserved.

2021-10-10T15:00:00Z